Press Releases

 
Press Releases
  Date Title View
Feb 6, 2017
LEXINGTON, MA -- (Marketwired) -- 02/06/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will participate at the 2017 Rare Disease, Biopharma One-on-One D...
PDF
Jan 25, 2017
LEXINGTON, MA -- (Marketwired) -- 01/25/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Noninfectious Anterior Uveitis: Enrollment of first-ever vehicle-controlled Phase 3 clinical trial is expected to begin in the second quarter of 2017. Sjögren-Larsson Syndrome...
PDF
Nov 22, 2016
LEXINGTON, MA -- (Marketwired) -- 11/22/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the 28th Annual Piper Jaffray Healthcare Conferen...
PDF
Nov 14, 2016
LEXINGTON, MA -- (Marketwired) -- 11/14/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today reported third quarter 2016 financial results. "We are extremely pleased with the progress we have made this year with our nove...
PDF
Nov 9, 2016
LEXINGTON, MA -- (Marketwired) -- 11/09/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Stifel 2016 Healthcare Conference on Wednesda...
PDF
Nov 8, 2016
LEXINGTON, MA -- (Marketwired) -- 11/08/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced it will issue financial results for the third quarter ended September 30, 2016 on Monday, November 14, 2016, prior to the market...
PDF
Nov 7, 2016
LEXINGTON, MA -- (Marketwired) -- 11/07/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced an upcoming poster presentation at the 2016 American College of Allergy, Asthma and Immunology Annual Scientific Meeting to be h...
PDF
Sep 26, 2016
LEXINGTON, MA -- (Marketwired) -- 09/26/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) First-Ever Vehicle-Controlled Phase III Clinical Trial in Noninfectious Anterior Uveitis First-Ever Phase III Clinical Trial in Sjögren-Larsson Syndrome Allergic Conjunctivitis Phase IIb Clinical Trial Phase II...
PDF
Sep 14, 2016
LEXINGTON, MA -- (Marketwired) -- 09/14/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the appointment of Richard H. Douglas, Ph.D. to the Board of Directors of the Company. "We are extremely pleased that...
PDF
Sep 9, 2016
LEXINGTON, MA -- (Marketwired) -- 09/09/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will host a Research and Development Day to discuss the company's late-stage clinical programs in ocular inflammation and...
PDF
Page: FirstPrevious
2
... NextLast